Prothrombin complex concentrate - Harbin Shiheng Bioengineering Pharmaceutical
Latest Information Update: 25 Nov 2015
At a glance
- Originator Harbin Shiheng Bioengineering And Pharmaceutical
- Class Blood coagulation factors
- Mechanism of Action Blood coagulation factor replacements; Factor IX stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Haemophilia B
Most Recent Events
- 25 Nov 2015 Clinical trials in Haemophilia B in China (IV)